SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 5, 2012
||VENTRUS BIOSCIENCES, INC.
||(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation)
||(Commission File Number)
||(IRS Employer ID Number)|
|99 Hudson Street, 5th Floor, New York, New York
|(Address of principal executive offices)
|Registrant’s telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))|
Item 8.01. Other Events.
Attached hereto as Exhibit 99.1 is a PowerPoint presentation
that Ventrus Biosciences, Inc. will present at the Stifel Nicolaus 2012 Healthcare Conference on September 5, 2012, and also will
use for various investor presentations and which is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
||PowerPoint presentation of September 5, 2012.|
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
||VENTRUS BIOSCIENCES, INC.|
|Date: September 5, 2012
||/s/ David J. Barrett|
||David J. Barrett, Chief Financial Officer|